Bifogade filer
Completion of capital increase in Initiator Pharma
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Initiator Pharma A/S (“Initiator” or the “Company”) has today completed the capital increase directed at members of executive management and key management under the long term incentive program for 2023 (“LTI2023-program”), which was announced on 14 October 2024.
Today, the Company’s share capital has been increased by a total nominal amount of DKK 11,392.50, divided into 108,500 shares (the “New Shares”), as a result of a share issue to certain members of executive management and key management under the LTI2023 program.
The capital increase in connection with the subscription of New Shares by certain members of executive management and key management amounted to a nominal value of DKK 11,392.50, corresponding to 108,500 shares with a nominal value of DKK 0.105 each. The 108,500 New Shares were subscribed for by cash contribution at a price of DKK 0.105 per share, and as a result, the Company’s gross proceeds amount to a total of DKK 11,392.50.
The New Shares are subject to the same rights as existing shares under the Company’s articles of association and are expected to be admitted to trading on Nasdaq First North Growth Market under the existing ISIN code DK0060775872.
After the completion of the capital increase, the total nominal share capital of the company is DKK 5,896,627.905, divided into 56,158,361 shares with a nominal value of DKK 0.105 each, corresponding to 56,158,361 votes.
The Company’s updated articles of association are now available on the Company’s website, following registration with the Danish Business Authority.